The US Food and Drug Administration (FDA) has approved a “game-changer” in the field of HIV prevention with an injectable PrEP treatment.
Instead of a daily PrEP pill taken orally, patients would have an injectable treatment (which will be known as Apretude) given every two months following two initial injections given one month apart.